Track topics on Twitter Track topics that are important to you
Theravance is a biopharmaceutical company with a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies. Theravance is focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including respiratory disease, bacterial infections, and central nervous system (CNS)/pain. Theravance's key programmes include: RELVAR™ ELLIPTA™ or BREO™ ELLIPTA™ (FF/VI), ANORO™ ELLIPTA™ (UMEC/VI) and MABA (Bifunctional Muscarinic Antagonist-Beta2 Agonist), each partnered with GlaxoSmithKline plc, and its oral Peripheral Mu Opioid Receptor Antagonist program. By leveraging its proprietary insight of multivalency to drug discovery, Theravance is pursuing a best-in-class strategy designed to discover superior medicines in areas of significant unmet medical need.
901 Gateway Blvd.
South San Francisco
United States of America
J&J inked a global collaboration deal with Theravance Biopharma to develop a drug for IBD.
Ireland-incorporated Theravance Biopharma saw its shares rocket more than 16% to $28.38 in morning trading…
Theravance Biopharma's new-drug application for revefenacin, or TD-4208, as a once-daily treatment for patients with chronic -More-
Theravance Biopharma is teaming up with Janssen Biotech to develop a group of drugs for intestinal diseases such as ulcerative colitis and Crohn’s. Dublin, Ireland based-Theravance Biopharma (NASDAQ...
DUBLIN and HERTFORDSHIRE, England and PITTSBURGH, Jan. 29, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma") and Mylan N.V. (NASDAQ, TASE: MYL) ("Mylan") today an...
DUBLIN and HERTFORDSHIRE, England and PITTSBURGH, Jan. 29, 2018 /PRNewswire/ — Theravance Biopharma, Inc. (NASDAQ: TBPH) (“Theravance Biopharma”) and Mylan N.V. (NASDAQ, TA...
The Janssen Biotech unit of Johnson & Johnson will co-develop and market Theravance Biopharma's pan-Janus kinase inhibitor TD -More-
CANONSBURG (dpa-AFX) - Theravance Biopharma Inc. (TBPH) and Mylan N.V. (MYL) said that the U.S. Food and Drug Administration or FDA has accepted for review the companies' recently submitted New Dr...
Theravance is a biopharmaceutical company with a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies. Theravance is focused on the discove...
Innoviva is focused on bringing compelling new medicines to patients in areas of unmet need by leveraging its significant expertise in the development, commercialization and finan...
We have published hundreds of Theravance news stories on BioPortfolio along with dozens of Theravance Clinical Trials and PubMed Articles about Theravance for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Theravance Companies in our database. You can also find out about relevant Theravance Drugs and Medications on this site too.
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...
Asthma COPD Cystic Fibrosis Pneumonia Pulmonary Medicine Respiratory Respiratory tract infections (RTIs) are any infection of the sinuses, throat, airways or lungs. They're usually caused by viruses, but they can also ...